Neurogene Newsroom

William Blair Maintains Neurogene(NGNE.US) With Buy Rating

Futu NewsDec 21 02:31

William Blair Maintains Neurogene(NGNE.US) With Buy Rating

Futu NewsDec 13 00:32

William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)

TipRanksDec 13 00:28

H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $55

Futu NewsNov 25 20:39

Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Dow JonesNov 25 20:33

Neurogene Analyst Ratings

BenzingaNov 25 20:23

Positive Outlook on Neurogene's NGN-401 Despite Setback: Buy Rating Reaffirmed With $55 Price Target

TipRanksNov 25 19:56

TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating

Futu NewsNov 21 21:31

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46

Futu NewsNov 21 21:31

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46

Futu NewsNov 21 11:31

TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating

Futu NewsNov 21 08:31

Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating

TipRanksNov 21 08:20

Neurogene Is Maintained at Outperform by BMO Capital

Dow JonesNov 20 22:17

BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $60

Futu NewsNov 19 21:31

A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $46 to $60

Futu NewsNov 19 21:01

Neurogene Analyst Ratings

BenzingaNov 19 19:43

Positive Interim Clinical Data and Strategic Developments Justify Buy Rating for Neurogene

TipRanksNov 13 15:11

Positive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over Neurogene

TipRanksNov 13 15:07

Neurogene Price Target Raised to $72.00/Share From $45.00 by Leerink Partners

Dow JonesNov 12 22:40

Neurogene (NGNE) Receives a Buy From Stifel Nicolaus

TipRanksNov 12 22:19